Figure 3.

Frequency of [a] worsened and [b] new MS symptoms following SARS-CoV-2 vaccinations in German people with multiple sclerosis. Fatigue ([a]: 5·8% vs. 7·8%; [b]: 2·2% vs. 3·0%) and impaired walking ability ([a]: 4·0% vs. 5·5%; [b]: 2·1% vs. 2·7%) were on the one hand the most common [a] worsened MS symptoms and on the other hand the most prevalent [b] new MS symptoms after both the first (N=2346) and second SARS-CoV-2 vaccination (N=1835).

FDR – false discovery rate

MS – multiple sclerosis

p – p-value

PwMS – people with MS

q – adjusted p-values using the false discovery rate

SARS-CoV-2 – severe acute respiratory syndrome coronavirus 2.